In a phase I clinical trial of pembrolizumab in 29 patients with advanced bladder cancer patients whose tumors expressed ≥1 % PD-L1, RR was 24 %, including three cases of CR [46]. The gene discussed is CD274; the disease is urinary bladder cancer.